selected scholarly activity
-
conferences
- Multisystem immune-related adverse events from dual agent immunotherapy use. Journal of Clinical Oncology. 2023
- Abstract CT149: BOLD-100-001 (TRIO039): a phase 1b/2a dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced colorectal cancer: interim efficacy, safety and tolerability analysis. Cancer Research. CT149-CT149. 2023
- BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy. Journal of Clinical Oncology. 2022
- Recurrent disease in patients with stage III melanoma in the era of adjuvant immune and targeted therapy.. Journal of Clinical Oncology. e21570-e21570. 2021
- BOLD-100-001 (TRIO039): A phase Ib dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid tumors.. Journal of Clinical Oncology. TPS145-TPS145. 2021
- P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma. Journal for ImmunoTherapy of Cancer. A10-A11. 2020
- A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.. Journal of Clinical Oncology. 2599-2599. 2019
- A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.. Journal of Clinical Oncology. TPS9600-TPS9600. 2018
- A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).. Journal of Clinical Oncology. 409-409. 2018
- Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment. Cancer Research. 2017
- Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review.. Journal of Clinical Oncology. e21064-e21064. 2017
- KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.. Journal of Clinical Oncology. 9513-9513. 2016
- A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. Journal of Clinical Oncology. 2015
- 508 A phase Ib trial of AMG386 and temsirolimus in patients with advanced sold tumors (PJC-008/NCI#9041). European Journal of Cancer. 165-166. 2014
- Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM). Journal of Clinical Oncology. 2013
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Journal of Clinical Oncology. 2012
- A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).. Journal of Clinical Oncology. 3082-3082. 2012
- IMPROVED 6-MONTH SURVIVAL RATE IN SUBJECTS WITH PROSTATE STEM CELL ANTIGEN POSITIVE TUMORS IN A GLOBAL, RANDOMIZED PHASE 2 TRIAL COMPARING GEMCITABINE VS. GEMCITABINE + AGS-1C4D4 (ASP6182) IN METASTATIC PANCREATIC CANCER. Annals of Oncology. v12-v12. 2011
- Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 2011
- A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium.. Journal of Clinical Oncology. e14544-e14544. 2010
- Phase II study of vorinostat in patients with advanced melanoma.. Journal of Clinical Oncology. 8530-8530. 2010
- Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines.. Breast Cancer Research and Treatment. S207-S207. 2005
-
journal articles
- 44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy. Annals of Oncology. 35:S22-S22. 2024
- Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review. Surgical Oncology. 54:102077-102077. 2024
- An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent. Clinical Oncology. 36:243-253. 2024
- BOLD-100-001 (TRIO039): A phase 2 study of BOLD-100 in combination with FOLFOX in patients with advanced mCRC previously treated with FOLFOX/CAPOX—Efficacy and safety analysis.. Journal of Clinical Oncology. 42:143-143. 2024
- Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use. Current Oncology. 31:425-435. 2024
- Pembrolizumab-induced immune-related sclerosing cholangitis. BMJ Case Reports. 16:e256125-e256125. 2023
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. Journal for ImmunoTherapy of Cancer. 11:e006500-e006500. 2023
- Multisystem immune-related adverse events from dual agent immunotherapy use.. Journal of Clinical Oncology. 41:2635-2635. 2023
- Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition. Current Oncology. 30:4527-4537. 2023
- A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology. 13:3216-3226. 2022
- BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy.. Journal of Clinical Oncology. 40:3031-3031. 2022
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer. 160:1-11. 2022
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma. Current Oncology. 27:204-214. 2020
- Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma.. Current Oncology. 27:204-214. 2020
- Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review. Cancer Treatment Reviews. 87:102032-102032. 2020
- Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Current Oncology. 27:43-52. 2020
- Is Access to Care Associated With Stage at Presentation and Survival for Melanoma Patients?. Journal of Cutaneous Medicine and Surgery. 23:586-594. 2019
- Cobimetinib- and vemurafenib-induced granulomatous dermatitis and erythema induratum: A case report. SAGE Open Medical Case Reports. 7:2050313X1984735-2050313X1984735. 2019
- Update on Immunotherapeutics in the Management of Metastatic Melanoma.. Skin therapy letter. 24:8-11. 2019
- A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs. 34:231-235. 2016
- A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34:104-111. 2016
- A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. Journal of Clinical Oncology. 33:TPS9089-TPS9089. 2015
- Phase II trial of vorinostat in advanced melanoma. Investigational New Drugs. 32:526-534. 2014
- A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Investigational New Drugs. 32:243-249. 2014
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of Oncology. 24:1792-1801. 2013
- Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.. Annals of Oncology. 24:1792-1801. 2013
- Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).. Journal of Clinical Oncology. 31:9032-9032. 2013
- A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Investigational New Drugs. 30:1158-1163. 2012
- A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Investigational New Drugs. 29:1045-1049. 2011
- Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology. 29:4031-4031. 2011
- Baseline radiological staging in primary breast cancer: impact of educational interventions on adherence to published guidelines. Journal of Evaluation in Clinical Practice. 13:647-650. 2007